SuperworthLifeMD free cash flow LFMD
Cash from operations less capital spending, by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$11M
- Latest quarter, Q2 FY26
- −$7M
- −189% on a year earlier
- Fiscal year 2025
- $6.4M
- −59% on the year before
LifeMD's free cash flow was −$11M over the twelve months to Jun 30, 2026, down 163% on a year earlier.
In its latest quarter, Q2 FY26, it was −$7M, down 189% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $6.4M | −59% |
| FY2024 | $15.6M | +81% |
| FY2023 | $8.6M | n/a |
| FY2022 | −$23.3M | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$7M | −189% | −$11M | |
| Q1 FY26 | $339.4K | −88% | $3.8M | |
| Q4 FY25 | −$3.4M | −493% | $6.4M | |
| Q3 FY25 | −$944.4K | −116% | $10.7M | |
| Q2 FY25 | $7.9M | +102% | $17.4M | |
| Q1 FY25 | $3M | −41% | $13.5M | |
| Q4 FY24 | $875.4K | −84% | $15.6M | |
| Q3 FY24 | $5.8M | +450% | $20.3M | |
| Q2 FY24 | $3.9M | −16% | $15.6M | |
| Q1 FY24 | $5M | n/a | $16.3M | |
| Q4 FY23 | $5.6M | n/a | $8.6M | |
| Q3 FY23 | $1M | n/a | $1.1M |
Against its peers
Companies in Healthcare nearest LifeMD's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| LFMDLifeMD | −10.7% |
| KEQUKewaunee Scientific | 11.5% |
| ICCCImmucell | 4.5% |
| LFVNLifevantage | 9.1% |
| SPROSpero Therapeutics | n/m |
| APTAlpha Pro Tech | 10.3% |
| PDEXPro DEX | 3.4% |
| PLXProtalix BioTherapeutics | 3.7% |
| NATRNatures Sunshine Products | 8.5% |
| ATNMActinium Pharmaceuticals | n/m |
| ELMDElectromed | 3.8% |
| Peer median | 6.5% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on LifeMD
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.